The multiple activity of coronavirus in experimental medicine is against multiple coronaviruses. Broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic coronaviruses in humans, an orally biodegradable primary called EIDD-2801 (DD-N4-hydroxycytidine-5′-isopropyl ester).
It is. Epithelial cells of the respiratory tract. According to a new study published in the journal Science Translational Medicine. The study also found that, when used as a prophylactic, EIDD-2801 can prevent severe lung injury in infected mice.
Color scanning electron micrograph of a VERO E6 cell (blue) isolated from a patient sample, heavily infected with SARS-COV-2 virus particles (orange).
EIDD-2801 is an orally available form of the antiviral compound EIDD-1931 (N-D-N4-hydroxycytidine).
It can be taken as a pill and is properly absorbed to travel to the lungs. When administered as a treatment 12 or 24 hours after the onset of infection, EIDD-2801 can reduce the degree of lung damage and weight loss. This window of opportunity is expected to last longer in humans.
As the onset and death of coronavirus disease generally increases in humans compared to mice. Lead author Professor Ralph Barrick, a virologist at the University of North Carolina at Chapel Hill, said: “This new drug not only has high potential to treat patients with COVID-19.
But is also effective in treating other serious coronavirus infections. Compared to other possible COVID-19 treatments to be administered intravenously, EIDD-2801 can be administered orally in pill form.
In addition to ease of treatment, it offers a potential benefit for treating less sick patients or for prophylaxis, for example, in a nursing home where many people are exposed but not yet sick. An antiviral scientist from Vanderbilt University School of Medicine, Drs.
We are amazed at the potential of EIDD-1931 and EIDD-2801, as all of the coronavirus tested and COVID-19 have potential for oral treatment,” said Andrea Pruver. Center. In 2019, researchers reported that EIDD-1931 blocked the replication of a broad spectrum of coronaviruses.
They demonstrated the preclinical development of another antiviral drug, remedsvir, currently in clinical trials of patients with COVID-19. In the new study, they showed that viruses showing resistance to Remedisvir experienced high inhibition of EIDD-1931.
The study was co-authored by Drs. George Painter stated, “Viruses that carry remedies for virus resistance mutations are actually more sensitive to EIDD-1931 and, conversely, the two drugs can be combined for greater efficacy.”
Emory University and Drug Innovation Ventures in Emory (DRIVE).
A clinical study of EIDD-2801 in humans is expected to begin later this spring. If successful, the drug can be used not only to limit the spread of SARS-CoV-2, but also to control future outbreaks of other emerging coronavirus.
The first author from the University of North Carolina at Chapel Hill was Drs. Timothy Sheehan said, With three new human coronaviruses in the past 20 years, we may continue to see more. EIDD-2801 today promises not only to treat patients with COVID-19, but also to treat new coronaviruses that may arise in the future.